Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings

Revenue from Mounjaro more than doubled. - andy rain/epa/shutterstock/Shutterstock Eli Lilly reported higher third-quarter profit and raised its full-year outlook on surging demand for its GLP-1 weight-loss drugs, sending its shares higher in premarket trading. Revenue from Mounjaro more than doubled to $6.52 billion, while that from Zepbound almost tripled to $3.59 billion. Overall revenue rose 54%, beating Wall Street’s expectations. Most Read from The Wall Street Journal Shares in the company rose 5 ...